by David Cassak
The news last month that the five largest global orthopedics companies and the US Attorney’s office in New Jersey have...
Though government officials and critics in the press painted lucrative consulting arrangements as unscrupulous tools in the hands of Big Ortho, no one's happier to see them go than the orthopedics industry itself. Here’s how the details shake out for the industry, and why executives are actually relieved to have some sticky legal and moral issues disappear. Some even predict that the end result will be lower overhead for their companies.
by David Cassak
The news last month that the five largest global orthopedics companies and the US Attorney’s office in New Jersey have...
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.